iShares Biotechnology ETF (NASDAQ:IBB) Shares Purchased by Pursue Wealth Partners LLC

Pursue Wealth Partners LLC raised its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 1.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,545 shares of the financial services provider’s stock after buying an additional 213 shares during the period. iShares Biotechnology ETF comprises about 1.4% of Pursue Wealth Partners LLC’s holdings, making the stock its 23rd largest position. Pursue Wealth Partners LLC’s holdings in iShares Biotechnology ETF were worth $2,545,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Pinnacle Wealth Management Advisory Group LLC boosted its holdings in shares of iShares Biotechnology ETF by 8.3% in the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,931 shares of the financial services provider’s stock valued at $262,000 after buying an additional 148 shares in the last quarter. Corient Private Wealth LLC grew its holdings in shares of iShares Biotechnology ETF by 1.0% during the fourth quarter. Corient Private Wealth LLC now owns 86,700 shares of the financial services provider’s stock worth $11,778,000 after purchasing an additional 841 shares during the last quarter. Mmbg Investment Advisors CO. increased its position in shares of iShares Biotechnology ETF by 0.6% during the fourth quarter. Mmbg Investment Advisors CO. now owns 78,550 shares of the financial services provider’s stock worth $10,671,000 after purchasing an additional 495 shares in the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of iShares Biotechnology ETF by 7.6% in the 1st quarter. Oppenheimer & Co. Inc. now owns 35,747 shares of the financial services provider’s stock valued at $4,905,000 after purchasing an additional 2,532 shares during the last quarter. Finally, Chemistry Wealth Management LLC boosted its position in shares of iShares Biotechnology ETF by 20.6% in the 1st quarter. Chemistry Wealth Management LLC now owns 3,560 shares of the financial services provider’s stock valued at $488,000 after purchasing an additional 609 shares during the period. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Performance

NASDAQ:IBB opened at $145.50 on Thursday. iShares Biotechnology ETF has a 52-week low of $111.83 and a 52-week high of $150.17. The stock’s 50 day moving average price is $143.88 and its 200 day moving average price is $137.89.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.